Compositions and methods for determining cancer risk

The MCD test using biomarker expression levels and algorithms classifies cancer risk, enhancing early detection and treatment outcomes for multiple cancers.

WO2026128634A1 Publication Date: 2026-06-18BOARD OF RGT THE UNIV OF TEXAS SYST
0 Cites 0 Cited by

Patent Information

Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
BOARD OF RGT THE UNIV OF TEXAS SYST
Filing Date
2025-12-10
Publication Date
2026-06-18

AI Technical Summary

⚠Technical Problem

Current cancer screening methods are limited to detecting a single type of cancer and often require symptoms to be present, missing opportunities for early detection and increased treatment response, prolonged survival, and reduced economic burden.

⚗Method used

A multi-cancer detection (MCD) test that assesses the expression levels of multiple biomarkers (PSA free form, PSA bound form, total PSA, CEA, CA125, CYFRA21-1, ProSFTPB, CA19-9, LRG1, TIMP1, HE4, AFP, CA15-3, and REG3A) to determine a subject's risk of developing various cancers, using mathematical algorithms to classify individuals as high, normal, or low risk, and recommending appropriate diagnostic procedures.

🎯Benefits of technology

Enables early detection of multiple cancers, improving treatment response, prolonging survival, and reducing economic burden by identifying individuals at risk before symptoms appear.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 1
    Figure 1
  • Figure 2
    Figure 2
Patent Text Reader

Abstract

The present disclosure provides a multi-cancer detection test for determining the risk of developing any one of nine common and lethal cancers. The present disclosure further provides a multi-cancer detection test for determining the risk of developing an uncommon cancer. The present disclosure further provides methods and compositions for identifying the risk of developing a plurality of cancers comprising detecting an expression level of a plurality of biomarkers selected from the group consisting of PSA free form, PSA bound form, total PSA, CEA, CA125, CYFRA21-1, ProSFTPB, CA19-9, LRG1, TIMP1, HE4, AFP, CA15-3, and REG3A.
Need to check novelty before this filing date? Find Prior Art